Vertraagde tijd
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
42,48 USD | -2,76% | -4,78% | -16,95% |
11:38 | Bristol-Myers Squibb investeert in NeoPhore | MT |
21/05 | Bristol-Myers Squibb zegt dat US FDA actiedatum subcutane Nivolumab opnieuw heeft vastgesteld | MT |
Omzet 2024 * | 46,03 mld. 42,5 mld. | Omzet 2025 * | 46,06 mld. 42,52 mld. | Marktkapitalisatie | 85,69 mld. 79,11 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -5,41 mld. -5 mld. | Nettowinst (verlies) 2025 * | 10,22 mld. 9,44 mld. | EV/omzet 2024 * | 2,72 x |
Nettoschuld 2024 * | 39,31 mld. 36,3 mld. | Nettoschuld 2025 * | 32,04 mld. 29,58 mld. | EV/omzet 2025 * | 2,56 x |
K/w-verhouding 2024 * |
-16,1
x | K/w-verhouding 2025 * |
8
x | Werknemers | 34.100 |
Dividendrendement 2024 * |
5,69% | Dividendrendement 2025 * |
5,98% | Vrij verhandelbaar | 69,27% |
Recentste transcriptie over Bristol-Myers Squibb Company
1 dag | -2,89% | ||
1 week | -4,78% | ||
Lopende maand | -4,41% | ||
1 maand | -14,19% | ||
3 maanden | -16,79% | ||
6 maanden | -13,60% | ||
Lopend jaar | -16,95% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 53 | 01-02-15 | |
David Elkins
DFI | Director of Finance/CFO | 55 | 20-11-19 |
Greg Meyers
CTO | Chief Tech/Sci/R&D Officer | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Phyllis Yale
BRD | Director/Board Member | 66 | 20-11-19 |
Peter Arduini
BRD | Director/Board Member | 59 | 01-04-16 |
Derica Rice
BRD | Director/Board Member | 59 | 01-09-20 |
Datum | Koers | Variatie | Volume |
---|---|---|---|
22-05-24 | 42,48 | -2,76% | 0 |
21-05-24 | 42,51 | -2,68% | 28 599 |
20-05-24 | 43,68 | -0,84% | 16 133 |
17-05-24 | 44,05 | -0,15% | 24 402 |
16-05-24 | 44,12 | -1,11% | 31 089 |
uitgestelde koers London S.E., 22 mei 2024 om 10:00 uur
Meer koersenHerzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+37,78% | 723 mld. | |
+31,13% | 598 mld. | |
-3,51% | 364 mld. | |
+19,94% | 331 mld. | |
+5,14% | 288 mld. | |
+16,23% | 244 mld. | |
-4,83% | 208 mld. | |
+9,97% | 210 mld. | |
+9,32% | 169 mld. |